Table 2.
Subsequent endometrial cancer among invasive female breast cancer survivors according to ER and PR status
| Characteristic | Subsequent endometrial cancers in survivors of ER+PR+ breast cancer
|
Subsequent endometrial cancers in survivors of ER+PR− breast cancer
|
Subsequent endometrial cancers in survivors of ER−PR+ breast cancer
|
Subsequent endometrial cancers in survivors of ER−PR− breast cancer
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| O§ | E⋄ | SIR (95 % CI) | O | E | SIR (95 % CI) | O | E | SIR (95 % CI) | O | E | SIR (95 % CI) | |
| Total no. | 1427 | 898.54 | 1.59* (1.51–1.67) | 244 | 168.47 | 1.45* (1.27–1.64) | 63 | 34.27 | 1.84* (1.41–2.35) | 310 | 225.94 | 1.37* (1.22–1.53) |
| Age at breast cancer diagnosis, years | ||||||||||||
| 20–29 | 0 | 0.21 | 0 (0–17.19) | 0 | 0.04 | 0 (0–86.14) | 0 | 0.02 | 0 (0–165.95) | 0 | 0.21 | 0 (0–17.19) |
| 30–39 | 9 | 9.97 | 0.90 (0.41–1.71) | 3 | 1.58 | 1.90 (0.39–5.54) | 2 | 1.05 | 1.90 (0.23–6.85) | 7 | 5.81 | 1.20 (0.48–2.48) |
| 40–49 | 187 | 114.59 | 1.63* (1.41–1.88) | 24 | 13.73 | 1.75* (1.12–2.60) | 22 | 8.00 | 2.75* (1.72–4.16) | 54 | 38.45 | 1.40* (1.05–1.83) |
| 50–59 | 342 | 252.77 | 1.35* (1.21–1.50) | 53 | 47.32 | 1.12 (0.84–1.46) | 14 | 11.54 | 1.21 (0.66–2.04) | 96 | 76.77 | 1.25* (1.01–1.53) |
| 60–69 | 441 | 273.52 | 1.61* (1.47–1.77) | 88 | 54.95 | 1.60* (1.28–1.97) | 12 | 7.97 | 1.51 (0.78–2.63) | 90 | 61.63 | 1.46* (1.17–1.79) |
| 70+ | 448 | 247.48 | 1.81* (1.65–1.99) | 76 | 50.85 | 1.49* (1.18–1.87) | 48 | 5.69 | 2.29* (1.22–3.91) | 63 | 43.05 | 1.46* (1.12–1.87) |
| Latency period, months | ||||||||||||
| 6–11 | 70 | 61.17 | 1.14 (0.89–1.45) | 16 | 12.26 | 1.30 (0.75–2.12) | 3 | 1.76 | 1.71 (0.35–4.99) | 18 | 15.95 | 1.13 (0.67–1.78) |
| 12–59 | 616 | 404.36 | 1.52* (1.41–1.65) | 98 | 78.33 | 1.25* (1.02–1.52) | 21 | 12.44 | 1.69* (1.05–2.58) | 127 | 98.73 | 1.29* (1.07–1.53) |
| 60–119 | 508 | 302.14 | 1.68* (1.54–1.83) | 100 | 54.79 | 1.83* (1.49–2.22) | 24 | 11.95 | 2.01* (1.29–2.99) | 103 | 72.98 | 1.41* (1.15–1.71) |
| 120+ | 233 | 130.87 | 1.78* (1.56–2.02) | 30 | 23.10 | 1.30 (0.88–1.85) | 15 | 8.12 | 1.85* (1.41–2.35) | 62 | 38.28 | 1.62* (1.24–2.08) |
| Race | ||||||||||||
| Non-His# White | 1154 | 744.98 | 1.55* (1.46–1.64) | 194 | 136.95 | 1.42* (1.22–1.63) | 55 | 26.63 | 2.07* (1.56–2.69) | 217 | 168.97 | 1.28* (1.12–1.47) |
| His# White | 67 | 56.71 | 1.18 (0.92–1.50) | 10 | 11.85 | 0.84 (0.40–1.55) | 4 | 2.57 | 1.56(0.42–3.99) | 24 | 18.65 | 1.29 (0.82–1.91) |
| Black | 77 | 42.8 | 1.80* (1.42–2.25) | 10 | 10.41 | 0.96 (0.46–1.77) | 2 | 2.57 | 0.78(0.09–2.81) | 48 | 23.56 | 2.04* (1.50–2.70) |
| Others | 129 | 54.04 | 2.39* (1.99–2.84) | 30 | 9.26 | 3.24* (2.19–4.63) | 2 | 2.51 | 0.80 (0.10–2.88) | 21 | 14.76 | 1.42 (0.88–2.17) |
| Calendar year of breast cancer diagnosis | ||||||||||||
| 1992–1994 | 375 | 215.89 | 1.74* (1.57–1.92) | 55 | 43.93 | 1.25 (0.94–1.63) | 25 | 12.27 | 1.96* (1.27–2.90) | 82 | 59.23 | 1.38* (1.10–1.72) |
| 1995–1999 | 620 | 355.11 | 1.75* (1.61–1.89) | 115 | 62.89 | 1.83* (1.51–2.19) | 23 | 14.86 | 1.55 (0.98–2.32) | 122 | 86.03 | 1.42* (1.18–1.69) |
| 2000–2004 | 339 | 246.94 | 1.37* (1.23–1.53) | 60 | 46.68 | 1.29 (0.98–1.65) | 12 | 5.40 | 2.22* (1.15–3.88) | 72 | 59.42 | 1.21 (0.95–1.53) |
| 2005–2009 | 93 | 80.59 | 1.15 (0.93–1.41) | 14 | 14.98 | 0.93 (0.51–1.57) | 3 | 1.28 | 2.34 (0.48–6.85) | 34 | 21.26 | 1.60* (1.11–2.23) |
The bold values indicate the SIR (risk) for developing a second primary endometrial cancer was significantly increased
SIR standardized incidence ratios
*
P <0.05; Confidence Intervals are 95 %
§
Observed number
⋄
Expected number
#
Hispanic